This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Rigel Shares Get Crushed

Auster doesn't see any meaningful catalysts that would lift the stock in the next 12 months, but he notes that the company is starting a phase II trial for a proposed rheumatoid arthritis treatment in 2006. In addition, he says that through a strategic collaboration, Pfizer (PFE) may help take a Rigel asthma drug into human testing next year.

Rigel is also working with companies like Johnson & Johnson (JNJ), Merck (MRK) and Novartis (NVS) on development and marketing plans for its drugs.

"After the dust settles, we believe RIGL may present an interesting value play for patient, long-term-oriented investors," Auster says. However he downgraded the stock to market perform. Wachovia Capital Markets does and seeks to do business with companies covered in its research reports.

Mark Monane at equity research firm Needham also expects Rigel to discontinue R112 development. Needham says it expects to receive or intends to seek compensation for investment banking services from Rigel in the next three months.

Lei Zhong, an analyst at Banc of America Securities, says his firm has never viewed Rigel as "a one-drug wonder." He adds that "we continue to like Rigel's drug discovery platform focused on Syk kinase." Still, he downgraded the stock from neutral from buy and slashed his price target to $10 from $30. Banc of America Securities intends to seek or expects to receive compensation for investment banking services from Rigel in the next three months.

Rigel will conduct a conference call after the market closes Thursday to discuss the trial data.

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
GSK $47.29 0.00%
RIGL $4.09 0.00%
AAPL $124.75 0.00%
FB $80.78 0.00%
GOOG $524.05 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs